Ligufalimab

Names

[ CAS No. ]:
2428381-55-7

[ Name ]:
Ligufalimab

Biological Activity

[Description]:

Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity[1].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> Immunology/Inflammation >> Interleukin Related

[In Vitro]

Ligufalimab 结合人 CD47 抗原，EC50 值为 0.078 nM，KD 值为 0.152 nM[1]。 Ligufalimab (0-3000 nM) 不诱导红细胞血凝[1]。 Ligufalimab (0.1、1、10 µg/mL) 以剂量依赖性方式诱导 Raji、Jurkat 和 Ramos 细胞的吞噬作用[1]。

[In Vivo]

Ligufalimab(0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model) 抑制小鼠肿瘤生长[1]。 Animal Model: SCID/Beige mice (Raji xenograft model, MDA-MB-231 xenograft model)[1] Dosage: 0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model Administration: I.v. Result: Inhibited tumor growth with the tumor inhibition rate of 88.56%, 63.78% at 1, 0.1 mg/kg.

[References]

[1]. Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. J Immunother Cancer. 2022 Nov;10(11):e005517.  

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds